Some Tech Names Deliver - Cramer's Mad Money (4/28/16)

by: SA Editor Michael Hopkins


Some tech companies, like Apple, disappointed with recent results. Others, like Facebook and Amazon, among others, delivered for investors.

Cramer talks with executives from Domino's, Avnet and NXPI Semiconductors.

Is it time to get back into pharma?

Stocks discussed on the in-depth session of Jim Cramer's Mad Money Program, Thursday, April 28.

Despite rallying for most of the day on Thursday, the markets took a beating after Carl Icahn announced he sold his stake in Apple (NASDAQ:AAPL).

Jim Cramer's take? Ignore the noise.

In his Mad Money show on Thursday, Cramer told investment-minded viewers to make their own decisions, and not rely on the opinions of someone else. "Remember, it's your money, not his," he said.

And while some big tech names (like Apple) are getting pummeled due to missing first-quarter expectations, others are delivering for investors. They include:

Amazon (NASDAQ:AMZN): The company reported a first-quarter EPS beat and revenue of $29.13 billion that beat by $1.15 billion.

LinkedIn (LNKD): The company's latest report disappointed. For the quarter, LinkedIn reported EPS and revenue beats. Cramer said the company is seeing accelerating demand. "What a switch from the last report!"

Expedia (NASDAQ:EXPE): Wall Street was looking for a loss, but the online travel giant reported a profit.

Cramer also said MasterCard (NYSE:MA) and PayPal (NASDAQ:PYPL) delivered strong results.

The results Cramer highlighted during his show was Facebook (NASDAQ:FB), which the Mad Money host said "gave you everything you want" from an earnings report. The social media giant released results after the close on Wednesday.

Facebook's first-quarter results beat on both EPS and revenue. Ad revenue rose 57% year over year to $5.2 billion. Monthly Active Users (MAUs) rose 4% quarter over quarter and 15% year over year to 1.65 billion. Daily Active Users (DAUs) rose 5% quarter over quarter and 16% year over year to 1.09 billion.

"In a few short years, this company has literally changed our lives, making the sort of impact other companies can only dream of," Cramer said.

He pointed out that "a billion people" find an hour each day to spend on the social media platform. He also highlighted that Facebook "pivoted from a PC dinosaur to a mobile monster in no time flat," and that the company continues to build an ad platform that's engaging for both users and advertisers.

The key part of that ad platform? Its ability to reach the crucial Millennial demographic.

"The Facebook stock story is as unassailable as it can get," Cramer said, "and it's not done."

CEO interview - Domino's Pizza

Domino's Pizza (NYSE:DPZ) didn't deliver for investors in the first quarter. The company reported EPS and revenue misses for the three-month period.

Despite the lackluster numbers, CEO Patrick Doyle, a guest on Mad Money, said the pizza giant still sees "great momentum in the business overall." He also noted that the company's international business is strong.

Cramer suggested the food space is getting competitive. Doyle recognized that, but also said Domino's can take more share in the pizza business. He mentioned that the company can do that by offering "great food, consistent delivery and giving good value to our customers."

Domino's also has a decent cash position - about $200 million at the end of the quarter. When it comes to that cash, Doyle said the company will do "what will be best for our shareholders."

Pharma stocks: Better days are here?

Is the worst over for pharma?

After getting pummeled by both politicians and investors, the industry may see light at the end of a dark tunnel. Cramer pointed to some key deals in the space investors should closely watch.

First, Abbott Laboratories (NYSE:ABT) plans to acquire St. Jude Medical (NYSE:STJ) in a $25 billion transaction - a move that could make the combined company more competitive. "Boy, do I like this deal," Cramer said.

Also, Sanofi (NYSE:SNY) is bidding $9.3 billion for Medivation (NASDAQ:MDVN). And AbbVie (NYSE:ABBV) announced a $5.8 billion takeover of privately held Stemcentrx (STEMC).

Along with other M&A deals in the space, "putting it all together I'm seeing $45 billion in M&A in one day. That's incredible," Cramer said.

Other companies are gaining strength. Bristol-Myers Squibb (NYSE:BMY) may have reported "less than stellar numbers," but Cramer said the company is "doing OK as well." Celgene (NASDAQ:CELG) was another pharma he highlighted during the show.

Can biopharma "go from roving bear market to raging bull status?" Cramer said "we got a lot of signs the drought is over." He suggested it may be time to buy.

Focus on Avnet

Avnet's (NYSE:AVT) fiscal third-quarter EPS of $1.01 beat by 2 cents, but $6.17 billion in revenue missed by $140 million. Cramer noted Avnet is a key company to watch given its role as the top distributor of electronic components in the tech sector. And he had CEO Rick Hamada on the show to give some guidance on where the company is headed.

Hamada said the miss on revenue was concentrated in the hardware IT side of business. The component side was "on target," especially with sales in Europe.

The CEO said Avnet sees converged infrastructure as an important area of growth. Companies are looking for complete solutions with storage, servers, networking and virtualization management all in one piece, providing scalability.

Hamada couldn't say if all hardware business is soft, but nonetheless, it was a tough quarter for technology.

NXP Semiconductors delivers

NXP Semiconductors (NASDAQ:NXPI) has become a force in the industry. The company is the no. 1 provider of semiconductor technology to the automobile industry and is becoming a leader in the Internet of Things (IoT) space. It provides contactless bank card technology. NXPI also supplies technology to Apple. And it's supporting Amazon's Echo device.

The company reported Q1 EPS of $1.14 (a beat by 5 cents) and revenue $2.22 billion (a beat by $10 million).

CEO Rick Clemmer told Cramer the company's strength is in its broad product portfolio. NXPI also strives to be the leader in the spaces it serves. "One of the things that we have is the diversity of the portfolio, that will allow us the opportunity to grow no matter what," he said.

Are there worries about China? Clemmer said the big economy "certainly is not as robust" as it has been, but also that it's "steady as she goes" in terms of business.

Calls taken by Cramer

Deutsche Bank (NYSE:DB): Cramer said the stock is "done going down, since the dollar is done going up."

Lumber Liquidators (NYSE:LL): He suggested selling Lumber Liquidators and buying Home Depot (NYSE:HD).

Synergy Pharmaceuticals (NASDAQ:SGYP): Cramer noted the CFO has resigned. "We got to wait a little bit."

Abiomed (NASDAQ:ABMD): Cramer said he prefers Abbot or Edwards Lifesciences (NYSE:EW).


Jim Cramer's Action Alerts PLUS: Check out Cramer's multi-million dollar charitable trust portfolio and uncover the stocks he thinks could be HUGE winners. Start your FREE 14-day trial now!

Get Cramer's Picks by email - it's free and takes only a few seconds to sign up.